Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avutometinib and Defactinib with Gemcitabine/Nab-paclitaxel in PDAC
NCT05669482Phase 2Active, not recruiting
- Sponsor
- Verastem Oncology
- Start
- Mar 2023
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of avutometinib, defactinib in pancreatic ductal adenocarcinoma (PDAC), sponsored by Verastem Oncology. Started Mar 2023; status: active, not recruiting.
02
Drugs
avutometinibdefactinib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05669482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05669482.